UCB will be at the AAN 2024 Annual Meeting! Join us at booth 1483 to learn more about ZILBRYSQ.

US-ZL-2400019

 

ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive (Ab+).

The power to take
charge

of gMG—
every day1,2

gardener gardener

ZILBRYSQ is the first and only FDA-approved self-administered complement C5 inhibitor for the treatment of gMG in adult patients.

Explore the data

Statistically significant differences

vs placebo at Week 12 across multiple gMG outcome measures1

 

Improvement observed at Week 1

in change from baseline vs placebo across multiple gMG outcome measures2

 

Self-administered at home or away

with a ready-to-use subcutaneous injection1

C5=complement component 5.

References:

  1. ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc.
  2. Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7